According to Edward Dowd's tweet, Bernstein's recent sell-side note anticipates that Moderna ($MRNA) will see little to no revenue in the first quarter of the year. This analysis could impact investor sentiment and trading strategies as traders may adjust their portfolios in response to these expectations.